Saturday, July 27, 2024 12:45:20 PM
Recent EPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 08:30:06 PM
- ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer • PR Newswire (Canada) • 11/01/2024 12:57:00 AM
- ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer • PR Newswire (US) • 11/01/2024 12:57:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/07/2024 07:00:52 PM
- ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress • PR Newswire (Canada) • 09/13/2024 09:19:00 PM
- ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress • PR Newswire (US) • 09/13/2024 09:19:00 PM
- ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference • PR Newswire (Canada) • 09/11/2024 08:05:00 PM
- ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/11/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 06:03:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:57:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:17:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:01:43 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 11:00:44 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 • PR Newswire (US) • 08/05/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 • PR Newswire (Canada) • 08/05/2024 11:00:00 AM
- ESSA Pharma to Present at the JonesHealthcare Seaside Summit • PR Newswire (Canada) • 07/08/2024 08:05:00 PM
- ESSA Pharma to Present at the JonesHealthcare Seaside Summit • PR Newswire (US) • 07/08/2024 08:05:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:00:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (Canada) • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:01:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:00:36 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (Canada) • 05/14/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:17:29 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (Canada) • 04/09/2024 12:00:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM